Survodutide

Plain-English version: survodutide is a small engineered protein (a "peptide") that mimics two of your body's own gut and pancreas hormones at the same time. One half acts like GLP-1, the hormone behind drugs such as Ozempic and Wegovy, which reduces appetite and steadies blood sugar. The other half acts like glucagon, a hormone that tells the liver to release stored energy and burn fat. Combining the two in one molecule is the whole idea — the appetite-lowering GLP-1 side is meant to drive weight loss, while the glucagon side adds extra fat-burning and targets the liver specifically.

"Survodutide" is the drug name; BI 456906 is the internal development code you will see in the scientific papers. It was created by Boehringer Ingelheim in partnership with Zealand Pharma and is given as a once-weekly injection under the skin. The molecule was deliberately tuned to a specific balance of glucagon-to-GLP-1 activity — enough glucagon signaling to boost energy expenditure and liver-fat oxidation, but enough GLP-1 signaling to keep blood sugar under control rather than letting glucagon push it up.^[1]

The credibility caveat, stated up front: survodutide is investigational. As of 2026 it is not approved by the FDA (or any major regulator) for obesity, MASH, diabetes, or any other use. What exists is three published Phase 2 randomized trials in humans — promising, industry-sponsored, mid-stage evidence. The larger Phase 3 program (the SYNCHRONIZE obesity trials and a MASH trial) is still underway, and those are the studies that ultimately decide whether survodutide becomes an approved medicine. For how investigational peptides are regulated, see Are Peptides Legal?

Takeaway first: survodutide works by pressing two hormone "buttons" at once. The GLP-1 button lowers appetite and protects blood-sugar control; the glucagon button raises energy burn and pushes the liver to oxidize (burn off) its own stored fat. The bet the developers are testing is that hitting both is better than hitting GLP-1 alone — especially for the liver.^[1]

1. GLP-1 receptor activation — the appetite and blood-sugar arm

GLP-1 (glucagon-like peptide-1) is a natural gut hormone released after you eat. Activating its receptor slows stomach emptying, signals fullness to the brain, and boosts insulin release when blood sugar is high. This is the same mechanism behind semaglutide and the GLP-1 portion of tirzepatide, and it is the main driver of appetite reduction and weight loss.

2. Glucagon receptor activation — the fat-burning and liver arm

Glucagon is often thought of only as the hormone that raises blood sugar, which sounds like the opposite of what you want. But at the liver, glucagon-receptor activation also increases fatty-acid oxidation (burning fat for fuel) and raises overall energy expenditure. In survodutide, the concurrent GLP-1 activity is what keeps the glucagon side from worsening glucose control — a balance confirmed in the type 2 diabetes trial, where blood-sugar (HbA1c) actually improved despite the glucagon component.^[3] The rationale specifically tested in the MASH trial is that this glucagon-driven hepatic fat oxidation could make a dual agonist more effective against fatty-liver disease than a GLP-1 drug on its own.^[1]

Why the combination is the point

Two arms working together are meant to be complementary: GLP-1 reduces how much you eat, and glucagon increases how much energy you burn and how much liver fat you clear. That is the mechanistic story behind survodutide being developed for two overlapping conditions — obesity and MASH — which frequently occur in the same person and share the same underlying metabolic problem.

What we do NOT know

All of the above is grounded in published Phase 2 human trials, which is a stronger evidence base than most research peptides have. But the long-term picture is still open: there are no published Phase 3 outcomes, no confirmed data on whether liver improvements translate into fewer cirrhosis or cardiovascular events over years, and the ideal glucagon-to-GLP-1 balance for real-world use is still being refined. Mechanism plus mid-stage efficacy is not the same as proven long-term benefit.

How to read this section: for each area we give the plain-English claim, the mechanism, the population actually studied, the observed effect with real numbers, and the limitation. Unlike most research peptides, survodutide has genuine human trial data — but it is all Phase 2, all industry-sponsored, and none of it is yet confirmed in Phase 3.

Weight loss (obesity)

Claim: produces substantial weight loss in people with obesity. Mechanism: GLP-1-driven appetite suppression plus glucagon-driven energy expenditure. Population: 386 treated adults with a BMI of 27 or higher and without diabetes, over 46 weeks. Effect: at the 4.8 mg weekly dose, average body-weight change was −14.9% (95% CI −16.9 to −13.0) versus −2.8% on placebo, under the primary "treatment-policy" estimand — the analysis that counts everyone as assigned, including those who stopped the drug.^[2] Limitation: Phase 2, 46 weeks only. You may see an "18.7%" figure quoted elsewhere; that comes from the on-treatment ("trial-product") estimand, which estimates the effect if everyone had stayed on drug — a legitimate but more optimistic number. The 14.9% treatment-policy result is the more conservative, real-world headline. This is the data behind survodutide's place in the weight-loss conversation.

Liver disease (MASH) improvement

Claim: improves the liver disease MASH without worsening scarring (fibrosis). Mechanism: glucagon-receptor activation drives the liver to burn its stored fat, directly targeting the fat accumulation that fuels MASH. Population: 293 adults with biopsy-confirmed MASH and fibrosis stages F1–F3, over 48 weeks. Effect: the primary endpoint — histologic MASH improvement without worsening of fibrosis — was met by 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) of survodutide groups, versus just 14% on placebo (P<0.001 for the dose-response).^[1] Limitation: this is MASH improvement, not "resolution" or a cure, and it is a 48-week biopsy endpoint, not a long-term outcome like preventing cirrhosis. Be wary of any source claiming survodutide produces "up to 83% MASH resolution" — that figure is not supported by the trial's primary endpoint.

Liver scarring (fibrosis) improvement

Claim: may reduce liver scarring, not just liver fat. Mechanism: reduced hepatic fat and inflammation over time can allow some fibrosis to regress. Population: the same 293-person MASH trial. Effect: improvement of fibrosis by at least one stage occurred in 34% (2.4 mg), 36% (4.8 mg), and 34% (6.0 mg) of survodutide groups versus 22% on placebo.^[1] Limitation: the fibrosis benefit is more modest than the MASH-improvement benefit and the gap over placebo is narrower; longer trials are needed to confirm it.

Blood-sugar control (type 2 diabetes)

Claim: lowers blood sugar and body weight in type 2 diabetes despite its glucagon activity. Mechanism: GLP-1 activity offsets glucagon's glucose-raising tendency, netting improved control. Population: adults with type 2 diabetes in a randomized, double-blind, placebo-controlled dose-finding trial that also included an open-label semaglutide comparator arm. Effect: survodutide produced dose-dependent reductions in HbA1c and body weight versus placebo, confirming that glycemic control is maintained (not worsened) by the glucagon component.^[3] Limitation: the semaglutide arm was open-label (not blinded), so this is not a rigorous head-to-head efficacy comparison; it provides context, not a winner.

The honest bottom line on "benefits"

• Real human data exist — three Phase 2 randomized trials — which puts survodutide well ahead of most peptides that only have animal studies.
• But it is all Phase 2. No Phase 3 efficacy or long-term outcome data are published. Weight-regain after stopping is expected, as with the whole GLP-1 class.
• All trials are industry-sponsored by Boehringer Ingelheim; independent replication is limited.
• Watch the numbers you are quoted. "18.7%" weight loss and "83% MASH resolution" are inflated or incorrect versions of the real 14.9% and 62%-improvement figures.

Read this first: there is no approved survodutide dose, because the drug is not approved and Phase 3 is still selecting the final regimen. The doses below are the ones used in published Phase 2 trials. They are described for understanding and completeness, not as a protocol to self-administer an unapproved, trial-only molecule.

Phase 2 dosing by indication

Indication	Trial	Doses tested (weekly SC)	Structure	Duration
Obesity (no diabetes)	Phase 2 (Lancet D&E 2024)	0.6 / 2.4 / 3.6 / 4.8 mg	20-week escalation + 26-week maintenance	46 weeks
MASH + fibrosis	Phase 2 (NEJM 2024)	2.4 / 4.8 / 6.0 mg	24-week escalation + 24-week maintenance	48 weeks
Type 2 diabetes	Phase 2 (Diabetologia 2024)	Dose-response range vs placebo & open-label semaglutide	Dose-finding	—

Two important corrections to numbers that circulate online: the obesity trial did not test a 6 mg dose — 6 mg appears only in the MASH trial. And the two lead trials used different escalation lengths (a slower 20-week ramp in obesity, a faster 24-week ramp in MASH), which is why you should not assume one universal titration schedule.^[1][2]

Why the slow escalation

Like all GLP-1-family drugs, survodutide is titrated up gradually to manage gastrointestinal side effects. The dose starts low and steps up every few weeks so the gut can adapt. Survodutide's ramp is if anything more cautious than semaglutide's, because the added glucagon activity increases the GI burden — in the obesity trial the escalation phase alone ran 20 weeks before the maintenance dose was reached.^[2] If a dose step is not tolerated (severe nausea, vomiting, dehydration), the clinical approach is to hold at the current step longer before advancing rather than pushing through.

Reconstitution math (for understanding only)

The clinical trials used pre-filled pen injectors, not vials that patients mix themselves. Any "survodutide" powder sold for reconstitution is unregulated research material of unverified identity (see Sourcing & Quality below). We include the math only so you understand how weekly-dose peptides are prepared in general. The core formula is:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: a hypothetical 10 mg vial reconstituted with 1 mL of bacteriostatic water gives 10 ÷ 1 = 10 mg/mL. To draw a 4.8 mg dose: 4.8 ÷ 10 = 0.48 mL, which is 48 units on a standard 100-unit insulin syringe. A 2.4 mg dose would be 0.24 mL, or 24 units. You can check volumes with the peptide calculator and bacteriostatic water calculator. Again: this is educational, not a recommendation to inject an investigational compound.

Administration, timing, and cycling

• Route: subcutaneous injection, once weekly (clinical trials used an auto-injector pen).
• Timing: the same day each week, any time of day, with or without food.
• No cycling: like the rest of the GLP-1 class, survodutide is designed for continuous use, not on/off cycles. It does not build tolerance the way some peptides do.
• After stopping: weight regain is expected, consistent with every drug in this class — the effects depend on ongoing use.

See the injection technique guide and the peptide storage guide for general handling.

Straight talk: in the Phase 2 trials, survodutide's side effects were dominated by gastrointestinal (GI) symptoms — nausea, diarrhea, and vomiting — concentrated during the dose-escalation period. This is the same pattern as the whole GLP-1 class, but somewhat heavier, because the glucagon component adds to the GI load. Serious adverse events were uncommon and similar to placebo. There are no published Phase 3 or long-term safety data yet, so this is mid-stage reassurance, not a final safety verdict.

Reported side effects from the Phase 2 trials

The clearest per-symptom numbers come from the MASH trial, which reported the most common adverse events for survodutide versus placebo:^[1]

Effect	Survodutide	Placebo	Notes
Nausea	66%	23%	Most common; peaks during titration
Diarrhea	49%	23%	Usually mild–moderate
Vomiting	41%	4%	Substantial during dose escalation
Serious adverse events	8%	7%	Similar between groups

The obesity trial showed the same picture from a different angle: adverse events occurred in 91% (281/309) of survodutide recipients versus 75% (58/77) on placebo, and were predominantly gastrointestinal (75% vs 42%). The overall study completion rate was 60.4%, reflecting meaningful GI-driven dropout during titration.^[2] That completion figure is the single most important practical tolerability question survodutide carries into Phase 3: the benefits are real, but a notable share of people struggle to stay on the drug through the ramp-up.

The glucagon component: what is different

Because survodutide activates the glucagon receptor — which pure GLP-1 drugs do not — it can produce a small, class-typical increase in heart rate and, in some people, transient increases in liver enzymes during therapy. The paradox worth understanding: survodutide is being developed for liver disease and improved liver histology overall in the MASH trial, but individual patients can still show temporary enzyme fluctuations that warrant monitoring. Its concurrent GLP-1 activity is what keeps the glucagon arm from raising blood sugar; glycemic control was maintained in the diabetes trial.^[3]

GLP-1 class safety considerations (apply to survodutide)

Survodutide has not been on the market long enough to have its own label warnings, but the established risks of the GLP-1 drug class should be assumed until Phase 3 and post-market data say otherwise:

• Acute pancreatitis: a recognized class concern; persistent severe abdominal pain warrants stopping and medical evaluation.
• Thyroid C-cell tumors: approved GLP-1 drugs carry a boxed warning based on rodent findings; survodutide's specific risk will be defined through its trial and surveillance data.
• Gallbladder problems: rapid weight loss raises the risk of gallstones and cholecystitis.
• Dehydration and kidney strain: usually a downstream consequence of heavy nausea and vomiting — hydration matters.
• Hypoglycemia: uncommon alone but rises sharply when combined with insulin or sulfonylureas.

Who should be most cautious, and drug interactions

• Personal or family history of medullary thyroid carcinoma or MEN 2: a precautionary class contraindication.
• Pregnancy and breastfeeding: no adequate safety data — avoid.
• Severe GI disease (gastroparesis, recurrent pancreatitis, active IBD flare): avoid.
• Insulin or sulfonylureas: doses often need lowering to prevent hypoglycemia.
• Oral medications (contraceptives, levothyroxine, warfarin, narrow-therapeutic-index drugs): delayed gastric emptying can alter absorption — monitor.
• Other GLP-1 drugs (semaglutide, tirzepatide, retatrutide, liraglutide): do not stack.

For broader context see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: survodutide is not something you can legitimately buy and use. It is an investigational drug available only through clinical trials. Anything labeled "survodutide" or "BI 456906" on a research-peptide website is unregulated material of unverified identity and purity — not the clinical-grade molecule Boehringer Ingelheim and Zealand Pharma studied.

Legal and regulatory status (2026)

• Not FDA-approved for obesity, MASH, diabetes, or any other indication as of 2026.
• Phase 3 in progress: the SYNCHRONIZE obesity program and a Phase 3 MASH trial are ongoing; these readouts, not the current Phase 2 data, will determine any approval. Realistic approval timing depends entirely on those results.
• Not available outside trials: there is no approved, prescribable survodutide product. The only legitimate access is enrollment in an active clinical trial.
• Research-market product is unregulated: gray-market survodutide has no verified identity, purity, or sterility, and is not the trial molecule.

If you are evaluating any research peptide vial

The same quality principles that apply to any unregulated peptide apply here — but with survodutide the more important point is that no gray-market source can be trusted to be the real, correctly folded, correctly dosed molecule. For general due-diligence, a credible research product should show:

• Third-party Certificate of Analysis (COA): independent HPLC purity plus mass-spectrometry identity, referencing the exact lot.
• Endotoxin (LAL) testing: essential for anything intended for injection.
• Proper form: lyophilized powder in a sealed, light-protected vial — not pre-mixed "ready to use" liquid.

Red flags

• No COA, or a COA from the seller instead of an independent lab
• Explicit human-use or medical claims (a sign of a non-compliant vendor)
• Prices far below the market, or dose/identity claims that cannot be verified

For the full legal picture, read Are Peptides Legal?

Survodutide belongs to the newer wave of multi-receptor metabolic drugs. None of these comparisons are backed by rigorous blinded head-to-head trials — they contrast mechanisms and separate trial results, which is not the same as a direct competition. For the class background, see the complete GLP-1 guide.

Compound	Receptor targets	Status	How it relates to survodutide
Survodutide	GLP-1 + glucagon	Phase 3 (investigational)	The reference here — dual agonist with a liver (MASH) focus
Mazdutide	GLP-1 + glucagon	Investigational	Closest analogue — same dual targets, different developer
Retatrutide	GLP-1 + GIP + glucagon	Investigational	Adds GIP to survodutide's formula; a "triple agonist"
Tirzepatide	GLP-1 + GIP	FDA-approved	Different dual strategy — targets GIP, not glucagon
Semaglutide	GLP-1 only	FDA-approved	The single-target benchmark survodutide is built to exceed on liver fat

The key conceptual point: survodutide's glucagon arm is what sets it apart from tirzepatide and semaglutide and is the basis for its MASH development. Mazdutide shares that same glucagon-based approach, while retatrutide layers on a third receptor (GIP). Read the full Survodutide vs Tirzepatide comparison for a deeper look at the dual-agonist trade-offs.